# Strategic Proposal: Proactive Market & Regulatory Intelligence Agent

**TO:** Murat Goeker (CIO) & Ivan O'Dwyer (Head of AI)
**FROM:** Johann Alberts
**SUBJECT:** Blueprint for the "Deep Research Agent" – Driving Proactive Compliance and Commercial Foresight

---

## 1. Executive Summary
Ideogen’s competitive advantage rests on its speed: achieving 6–12 months to market. To sustain this against rapid market shifts and a volatile regulatory environment—including the requirements of **GxP**, **21 CFR Part 11**, **EU Annex 11**, **GVP (Pharmacovigilance)**, and **GDPR**—a system that anticipates change is essential.

This proposal outlines the **Deep Research Agent**, a strategic automation designed to continuously monitor global regulatory proposals, competitor pipelines, and emerging market data across Ideogen’s core focus areas: **Haemo-Oncology/PTCL, Hematology, Infectious Disease, Metabolism Disorder, and Pulmonary/Critical Care.**

## 2. Agent Architecture (LangGraph Workflow)
The agent utilizes a four-stage state machine designed for high-accuracy pharmaceutical research:

### Stage 1: `search_reports` (Discovery)
* **Action:** Scans official EU/FDA/EMA portals, industry journals, and competitor press releases.
* **Focus:** Identifies regulatory proposal metadata and competitive pipeline changes (e.g., Phase III results, M&A activity).
* **Tooling:** GPT-4o with Web Search / Custom Scrapers.

### Stage 2: `evaluate_reports` (Validation)
* **Action:** Filters raw results using a Pydantic-enforced `RelevanceEvaluation` schema.
* **Criteria:** Assigns a score (0-100) based on source credibility (peer-reviewed journals vs. noise) and regulatory impact.
* **Logic:** Ensures the subsequent analysis is grounded in verified data.

### Stage 3: `analyse_reports` (Synthesis)
* **Action:** Performs cross-source synthesis to identify emerging threats and compliance gaps.
* **Environment:** Runs on the **NVIDIA DGX Spark** unit using **Ollama** to maintain data residency and privacy for sensitive clinical insights.

### Stage 4: `extract_intelligence` (Structuring)
* **Action:** Restructures the synthesized text into a structured JSON/Pydantic format for the executive dashboard.
* **Output:** Extracts **Emerging GxP Requirements**, **Competitive Threats**, and **Projected Market Shifts**.

## 3. Compliance & Governance Integration
To satisfy **21 CFR Part 11** and **Annex 11** requirements, the agent is built with:
* **Audit Trails:** Full execution logging via **Langfuse** to provide a traceable record of how intelligence was gathered.
* **Fact-Grounding (RAG):** Utilization of a Vector DB (Qdrant/Pinecone) to ensure the LLM outputs are linked to original regulatory or clinical source texts.
* **Observability:** Integration with **Prometheus/Grafana** to monitor system health and data recency.

## 4. Operational Impact
* **Regulatory Submissions Accelerator:** Feeds the latest compliance checklists to the drafting agents.
* **Molecule to Market Research:** Provides real-time competitive benchmarking for pricing and GTM strategies.
* **HCP Targeting Intelligence:** Updates feature pipelines with emerging clinical trends and new diagnostic codes.

---

## 5. Visual Dashboard Mockup (Concept)
### I. System Health
* **Agent Latency:** 135 min (Goal: <180)
* **Data Recency:** 6 hours
* **Infrastructure:** DGX GPU Load (45%)

### II. Regulatory Foresight (Alerts)
* **High Risk:** EU Annex 11 Audit Trail Re-clarification
* **Medium Risk:** GDP Temperature Logging Update
* **Trend:** 11% increase in rare disease diagnostic code usage

### III. Commercial Intelligence
* **Competitor Monitor:** PTCL Phase 3 results detected (Competitor X).
* **Strategic Response:** Update Field Sales Assist Agent with comparative safety RWE.